Genisphere

NEW YORK (GenomeWeb News) – Genisphere said today it has licensed its 3DNA Signal Amplification technology to Chembio Diagnostics.

Quest Diagnostics has been awarded US Patent No. 8,346,485, "Methods and apparatuses for estimating initial target nucleic acid concentration in a sample by modeling background signal and cycle-dependent amplification efficiency of a polymerase chain reaction."

Genisphere and the Lankenau Institute for Medial Research said this week that they are expanding their collaboration on the development of microRNA biomarkers for ulcerative colitis to include Crohn's disease and other inflammatory bowel disorders.

NEW YORK (GenomeWeb News) –Genisphere and the Lankenau Institute for Medical Research today said that they have expanded their research collaboration aimed at identifying microRNA biomarkers to include Crohn's Disease and other inflammatory bowel disorders.

Hahn-Schickard-Gesellschaft of Villingen-Schwenningen, Germany, has received US Patent No.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Affymetrix plans to offer Genisphere's miRNA reagents for use with its GeneChip miRNA 2.0 Arrays under a new license agreement, Affy said today.

Genisphere said this week that it has signed deals licensing its RNA target amplification and FlashTag Biotin microRNA labeling technologies to Affymetrix.

Quest Diagnostics, Albert Einstein College of Medicine, Riken, Genisphere, Stanford, DNA Electronics, US Genomics, Qiagen, and others awarded US patents.

Pages

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.